CA2799205A1 - Fast results hybrid capture assay and associated strategically-truncated probes - Google Patents
Fast results hybrid capture assay and associated strategically-truncated probes Download PDFInfo
- Publication number
- CA2799205A1 CA2799205A1 CA2799205A CA2799205A CA2799205A1 CA 2799205 A1 CA2799205 A1 CA 2799205A1 CA 2799205 A CA2799205 A CA 2799205A CA 2799205 A CA2799205 A CA 2799205A CA 2799205 A1 CA2799205 A1 CA 2799205A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- hpv
- sample
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000523 sample Substances 0.000 title claims abstract description 408
- 238000003556 assay Methods 0.000 title description 36
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 269
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 259
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 259
- 238000000034 method Methods 0.000 claims abstract description 87
- 108091033319 polynucleotide Proteins 0.000 claims description 76
- 102000040430 polynucleotide Human genes 0.000 claims description 76
- 239000002157 polynucleotide Substances 0.000 claims description 76
- 238000012217 deletion Methods 0.000 claims description 61
- 230000037430 deletion Effects 0.000 claims description 61
- 239000012472 biological sample Substances 0.000 claims description 18
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
- 239000002853 nucleic acid probe Substances 0.000 claims description 8
- 241000701806 Human papillomavirus Species 0.000 abstract description 239
- 238000001514 detection method Methods 0.000 abstract description 44
- 230000037029 cross reaction Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 88
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 78
- 239000003599 detergent Substances 0.000 description 78
- 239000013612 plasmid Substances 0.000 description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000011324 bead Substances 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- 230000009260 cross reactivity Effects 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 29
- LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 28
- 239000003153 chemical reaction reagent Substances 0.000 description 28
- 238000009396 hybridization Methods 0.000 description 28
- 239000011534 wash buffer Substances 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 230000000295 complement effect Effects 0.000 description 26
- 239000002585 base Substances 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 22
- 239000003085 diluting agent Substances 0.000 description 22
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 238000004925 denaturation Methods 0.000 description 20
- 230000036425 denaturation Effects 0.000 description 20
- 229960003964 deoxycholic acid Drugs 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- 230000005291 magnetic effect Effects 0.000 description 16
- 239000003391 RNA probe Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 14
- 108020004518 RNA Probes Proteins 0.000 description 14
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 11
- 239000003755 preservative agent Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- -1 stool) or tissue Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000002335 preservative effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000005298 paramagnetic effect Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000003196 chaotropic effect Effects 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000004584 polyacrylic acid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 108091093088 Amplicon Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002203 pretreatment Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000012203 high throughput assay Methods 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000321096 Adenoides Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000606153 Chlamydia trachomatis Species 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 210000002534 adenoid Anatomy 0.000 description 4
- 238000002869 basic local alignment search tool Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229940038705 chlamydia trachomatis Drugs 0.000 description 4
- 230000001268 conjugating effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 210000004910 pleural fluid Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 108020004394 Complementary RNA Proteins 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 229920004934 Dacron® Polymers 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000224527 Trichomonas vaginalis Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005294 ferromagnetic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 238000013038 hand mixing Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010008263 Cervical dysplasia Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 244000007853 Sarothamnus scoparius Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 235000019846 buffering salt Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005292 diamagnetic effect Effects 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000005447 environmental material Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108020004996 Heterogeneous Nuclear RNA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- LRUUNMYPIBZBQH-UHFFFAOYSA-N Methazole Chemical compound O=C1N(C)C(=O)ON1C1=CC=C(Cl)C(Cl)=C1 LRUUNMYPIBZBQH-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960003431 cetrimonium Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002889 diamagnetic material Substances 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003302 ferromagnetic material Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000002133 sample digestion Methods 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34794110P | 2010-05-25 | 2010-05-25 | |
| US61/347,941 | 2010-05-25 | ||
| PCT/US2011/037684 WO2011149897A1 (en) | 2010-05-25 | 2011-05-24 | Fast results hybrid capture assay and associated strategically-truncated probes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2799205A1 true CA2799205A1 (en) | 2011-12-01 |
Family
ID=44275651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2799205A Abandoned CA2799205A1 (en) | 2010-05-25 | 2011-05-24 | Fast results hybrid capture assay and associated strategically-truncated probes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9376727B2 (enExample) |
| EP (1) | EP2576840B1 (enExample) |
| JP (1) | JP6153866B2 (enExample) |
| AU (1) | AU2011258501B2 (enExample) |
| CA (1) | CA2799205A1 (enExample) |
| WO (1) | WO2011149897A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI394839B (zh) * | 2008-10-27 | 2013-05-01 | Qiagen Gaithersburg Inc | 快速結果雜交捕捉法及系統 |
| EP2528932B1 (en) * | 2010-01-29 | 2016-11-30 | QIAGEN Gaithersburg, Inc. | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids |
| CN105368982B (zh) | 2014-08-28 | 2019-01-29 | 杭州德同生物技术有限公司 | 一种高危型人乳头瘤病毒检测及分型方法 |
| JP7646548B2 (ja) * | 2019-01-03 | 2025-03-17 | 杭州諾輝健康科技有限公司 | ヒトパピローマウイルスを検出するための組成物及び方法 |
Family Cites Families (223)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732847A (en) | 1981-06-09 | 1988-03-22 | University Of Hawaii | Monoclonal antibodies for DNA-RNA hybrid complexes and their uses |
| FI63596C (fi) | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
| US4486536A (en) | 1982-05-28 | 1984-12-04 | Smithkline Diagnostics, Inc. | Specimen slide for occult blood testing |
| US4865980A (en) | 1982-12-29 | 1989-09-12 | University Of Hawaii | Monoclonal antibodies for DNA-RNA hybrid complexes and their uses |
| FI843529A0 (fi) | 1983-01-10 | 1984-09-10 | Gen Probe Inc | Foerfarande foer detektering, identifiering och kvantitering av organismer och virus. |
| US5288611A (en) | 1983-01-10 | 1994-02-22 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating organisms and viruses |
| US5200313A (en) | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US4743535A (en) | 1984-11-07 | 1988-05-10 | Miles Inc. | Hybridization assay employing labeled probe and anti-hybrid |
| EP0144914A3 (en) | 1983-12-12 | 1986-08-13 | Miles Inc. | Hybridization assay employing labeled pairs of hybrid binding reagents |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| FI71768C (fi) | 1984-02-17 | 1987-02-09 | Orion Yhtymae Oy | Foerbaettrade nykleinsyrareagenser och foerfarande foer deras framstaellning. |
| CA1260372A (en) | 1984-04-27 | 1989-09-26 | Elazar Rabbani | Hybridization method for the detection of genetic materials |
| CA1253777A (en) | 1984-06-01 | 1989-05-09 | Robert J. Carrico | Nucleic acid hybridization assay employing immobilized rna probes |
| US4563417A (en) | 1984-08-31 | 1986-01-07 | Miles Laboratories, Inc. | Nucleic acid hybridization assay employing antibodies to intercalation complexes |
| US4689294A (en) | 1984-11-19 | 1987-08-25 | Miles Laboratories, Inc. | Enhancement of hybridization of nucleic acids by anionic polymers |
| US5411857A (en) | 1985-07-31 | 1995-05-02 | Institut Nationale De La Sante | Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections |
| US5876922A (en) | 1985-07-31 | 1999-03-02 | Institute Pasteur | Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections |
| CA1276575C (fr) | 1984-11-30 | 1990-11-20 | Sylvie Beaudenon | Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus |
| US4751177A (en) | 1985-06-13 | 1988-06-14 | Amgen | Methods and kits for performing nucleic acid hybridization assays |
| ES8707343A1 (es) | 1985-06-13 | 1987-07-16 | Amgen | Un metodo para aislar una secuencia de acido nucleico objetivo seleccionada |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| ATE76429T1 (de) | 1986-03-21 | 1992-06-15 | Pasteur Institut | Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen. |
| US5750338A (en) | 1986-10-23 | 1998-05-12 | Amoco Corporation | Target and background capture methods with amplification for affinity assays |
| ES2112824T5 (es) | 1986-11-24 | 2008-03-01 | Gen-Probe Incorporated | Sondas de acidos nucleicos para deteccion y/o cuantificacion de organismos no virales. |
| AU619170B2 (en) | 1987-01-09 | 1992-01-23 | Abbott Laboratories | Diagnostic assays using nucleic acid probes |
| WO1988006634A1 (en) | 1987-02-26 | 1988-09-07 | The University Of Sydney | A method of detection of carcinogenic human papillomavirus |
| AU601021B2 (en) | 1987-03-11 | 1990-08-30 | Molecular Diagnostics, Inc. | Assay for necleic acid sequences in a sample |
| IL85551A0 (en) | 1987-04-01 | 1988-08-31 | Miles Inc | Rapid hybridization assay and reagent system used therein |
| DE3722968A1 (de) | 1987-07-11 | 1989-01-19 | Behringwerke Ag | Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine |
| US5656731A (en) | 1987-10-15 | 1997-08-12 | Chiron Corporation | Nucleic acid-amplified immunoassay probes |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| DE68916671T2 (de) | 1988-03-18 | 1995-03-02 | Baylor College Medicine | Mutationsnachweis durch kompetitiven Oligonukleotid-Priming. |
| US5374524A (en) | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
| FR2632956B2 (fr) | 1988-05-13 | 1991-07-12 | Pasteur Institut | Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus |
| NO165894C (no) | 1988-05-24 | 1991-04-24 | Gunnar Paulsen | Analysemetode for gener. |
| DE3826793A1 (de) | 1988-08-06 | 1990-03-08 | Behringwerke Ag | Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine |
| US5639871A (en) | 1988-09-09 | 1997-06-17 | Roche Molecular Systems, Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5447839A (en) | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5182377A (en) | 1988-09-09 | 1993-01-26 | Hoffmann-La Roche Inc. | Probes for detection of human papillomavirus |
| ATE168724T1 (de) | 1988-09-29 | 1998-08-15 | Chiron Corp | Nachweis eines polynukleotids durch ersätzung einer kette an einer fangsonde |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5077192A (en) | 1988-10-25 | 1991-12-31 | The General Hospital Corporation | Method of detecting antigenic, nucleic acid-containing macromolecular entities |
| CA1339729C (en) | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
| DE3838269A1 (de) | 1988-11-11 | 1990-05-17 | Behringwerke Ag | Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen |
| ATE118824T1 (de) | 1989-03-10 | 1995-03-15 | Amoco Corp | Immobilisierte oligonukleotidsonden und ihre verwendungen. |
| US5106727A (en) | 1989-04-27 | 1992-04-21 | Life Technologies, Inc. | Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers |
| US5863717A (en) | 1989-11-03 | 1999-01-26 | Abbott Laboratories | Use of conserved oligonucleotide primers to amplify human papillomavirus DNA sequences |
| US5580970A (en) | 1989-12-01 | 1996-12-03 | Amoco Corporation | Detection of HPV transcripts |
| WO1991008312A1 (en) | 1989-12-01 | 1991-06-13 | Gene-Trak Systems | Detection of hpv transcripts |
| US6174870B1 (en) | 1989-12-04 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of papillomavirus |
| US5811232A (en) | 1989-12-04 | 1998-09-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides for Papillomavirus |
| US5756282A (en) | 1989-12-04 | 1998-05-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for the diagnosis of papillomavirus |
| NL9000134A (nl) | 1990-01-19 | 1991-08-16 | Stichting Res Fonds Pathologie | Primers en werkwijze voor het detecteren van humaan papilloma virus genotypen m.b.v. pcr. |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| CA2039517C (en) | 1990-04-03 | 2006-11-07 | David Segev | Dna probe signal amplification |
| US5695926A (en) | 1990-06-11 | 1997-12-09 | Bio Merieux | Sandwich hybridization assays using very short capture probes noncovalently bound to a hydrophobic support |
| GB9015845D0 (en) | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5484699A (en) | 1990-09-28 | 1996-01-16 | Abbott Laboratories | Nucleotide sequences useful as type specific probes, PCR primers and LCR probes for the amplification and detection of human papilloma virus, and related kits and methods |
| WO1992008808A1 (en) | 1990-11-14 | 1992-05-29 | Siska Diagnostics, Inc. | Non-isotopic detection of nucleic acids using a polystyrene support-based sandwich hybridization assay and compositions useful therefor |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| WO1992011390A1 (en) | 1990-12-17 | 1992-07-09 | Idexx Laboratories, Inc. | Nucleic acid sequence detection by triple helix formation |
| FR2670797A1 (fr) * | 1990-12-20 | 1992-06-26 | Pasteur Institut | Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene. |
| US5219990A (en) | 1991-01-28 | 1993-06-15 | Biogen, Inc. | Papillomavirus e2 trans-activation repressors |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| FR2678284B1 (fr) | 1991-06-28 | 1993-10-08 | Pasteur Institut | Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes. |
| DK1298211T3 (da) | 1991-07-19 | 2006-11-13 | Univ Queensland | Polynukleotidsegment af HPV16-genom |
| US5543294A (en) | 1991-07-19 | 1996-08-06 | The Trustees Of Columbia University In The City Of New York | Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria |
| US5346811A (en) | 1991-07-22 | 1994-09-13 | Cerveceria Polar | Method and products for human papillomavirus detection |
| US5556748A (en) | 1991-07-30 | 1996-09-17 | Xenopore Corporation | Methods of sandwich hybridization for the quantitative analysis of oligonucleotides |
| EP0667918B1 (en) | 1991-11-14 | 2000-02-16 | Digene Diagnostics, Inc. | Non-radioactive hybridization assay and kit |
| US5981179A (en) | 1991-11-14 | 1999-11-09 | Digene Diagnostics, Inc. | Continuous amplification reaction |
| US5506105A (en) | 1991-12-10 | 1996-04-09 | Dade International Inc. | In situ assay of amplified intracellular mRNA targets |
| US5424413A (en) | 1992-01-22 | 1995-06-13 | Gen-Probe Incorporated | Branched nucleic acid probes |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| ES2126002T3 (es) | 1992-09-15 | 1999-03-16 | Dow Chemical Co | Modificacion de la resistencia al choque de termoplasticos. |
| EP0625213B1 (en) | 1992-10-09 | 1999-12-29 | VYSIS, Inc. | Assay methods |
| WO1994016108A1 (en) | 1993-01-15 | 1994-07-21 | The Public Health Research Institute Of The City Of New York, Inc. | Sensitive nucleic acid sandwich hybridization assays and kits |
| US6495676B1 (en) | 1993-04-13 | 2002-12-17 | Naxcor | Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
| US6277570B1 (en) | 1993-04-13 | 2001-08-21 | Naxcor | Nucleic acid sequence detection employing probes comprising non-nucleosidic coumarin derivatives as polynucleotide-crosslinking agents |
| CA2167838C (en) | 1993-07-23 | 1999-11-23 | Thomas B. Ryder | Methods for enhancing nucleic acid amplification |
| DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
| US5679509A (en) | 1993-09-28 | 1997-10-21 | University Of New Mexico | Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| DK145493D0 (da) | 1993-12-23 | 1993-12-23 | Dako As | Antistof |
| AUPM358894A0 (en) | 1994-01-31 | 1994-02-24 | Csl Limited | Modified papilloma virus l2 protein and vlps formed therefrom |
| JPH10500281A (ja) | 1994-02-14 | 1998-01-13 | ザ マクファーレーン バーネット センター フォー メディカル リサーチ リミテッド | 非病原性ｈｉｖ−１種 |
| WO1995022626A1 (en) | 1994-02-21 | 1995-08-24 | Stichting Researchfonds Pathologie | Human papilloma virus detection in a nucleic acid amplification process using general primers |
| DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| AUPM566794A0 (en) | 1994-05-17 | 1994-06-09 | University Of Queensland, The | Process and product |
| US6045995A (en) | 1994-08-24 | 2000-04-04 | Isis Pharmaceuticals, Inc. | Capillary electrophoretic detection of nucleic acids |
| US5622822A (en) | 1994-09-13 | 1997-04-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same |
| US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
| CA2200582C (en) | 1994-09-22 | 2007-03-27 | Merck & Co., Inc. | Dna encoding human papillomavirus type 6a |
| JP3093116B2 (ja) | 1994-09-30 | 2000-10-03 | 株式会社豊田中央研究所 | 核酸検出方法 |
| GB9420146D0 (en) | 1994-10-06 | 1994-11-23 | Cancer Res Campaign Tech | Papillomavirus vaccine |
| US6057099A (en) | 1994-12-02 | 2000-05-02 | Intelligene Ltd. | Detection of nucleic acid sequences |
| US20030104361A1 (en) | 1997-09-29 | 2003-06-05 | Susan Weininger | Method of detection of nucleic acids with a specific sequence composition |
| US5731153A (en) | 1996-08-26 | 1998-03-24 | The Regents Of The University Of California | Identification of random nucleic acid sequence aberrations using dual capture probes which hybridize to different chromosome regions |
| US5888724A (en) | 1995-02-17 | 1999-03-30 | The Trustees Of Columbia University In The City Of New York | Detection of high oncogenic-risk papilloma virus in high grade cervical lesions and cancers by a PCR/ELISA assay |
| DE19506561C1 (de) | 1995-02-24 | 1996-10-10 | Deutsches Krebsforsch | Verfahren zur Früherkennung von HPV-assoziierten Karzinomen bzw. von hochgradigen, durch HPV-verursachten Dysplasien |
| US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
| IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| US6458940B2 (en) | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
| US6509149B2 (en) | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
| WO1996040992A2 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Probe masking method of reducing background in an amplification reaction |
| DE19526386C1 (de) | 1995-07-19 | 1997-01-02 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| FR2737502B1 (fr) | 1995-07-31 | 1997-10-24 | Genset Sa | Procede de detection d'acides nucleiques utilisant des sondes nucleotidiques permettant a la fois une capture specifique et une detection |
| CA2237891C (en) | 1995-11-15 | 2013-07-30 | Gen-Probe Incorporated | Nucleic acid probes complementary to human papillomavirus nucleic acid and related methods and kits |
| US5888736A (en) | 1995-12-22 | 1999-03-30 | Visible Genetics, Inc. | Method, compositions and kit for detection and identification of microorganisms |
| US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| EP2368897B1 (en) | 1996-02-09 | 2016-10-19 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US5981173A (en) | 1996-02-14 | 1999-11-09 | Institut Pasteur | Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39 |
| US6511805B1 (en) | 1996-03-15 | 2003-01-28 | The Penn State Research Foundation | Methods for detecting papillomavirus DNA in blood plasma and serum |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| WO1998001148A1 (en) | 1996-07-09 | 1998-01-15 | President And Fellows Of Harvard College | Use of papillomavirus e2 protein in treating papillomavirus-infected cells and compositions containing the protein |
| US6218105B1 (en) | 1996-07-19 | 2001-04-17 | Kathleen S. Hall | High throughput papilloma virus in vitro infectivity assay |
| US5853993A (en) | 1996-10-21 | 1998-12-29 | Hewlett-Packard Company | Signal enhancement method and kit |
| US6265154B1 (en) | 1996-10-25 | 2001-07-24 | Abbott Laboratories | Nucleic acid primers and probes for detecting oncogenic human papillomaviruses |
| US6117631A (en) | 1996-10-29 | 2000-09-12 | Polyprobe, Inc. | Detection of antigens via oligonucleotide antibody conjugates |
| GB9624165D0 (en) | 1996-11-19 | 1997-01-08 | Amdex A S | Use of nucleic acids bound to carrier macromolecules |
| DE19648962C1 (de) | 1996-11-26 | 1998-02-26 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US6388065B1 (en) | 1996-11-27 | 2002-05-14 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | DNA for evaluating the progression potential of cervical lesions |
| US6110676A (en) | 1996-12-04 | 2000-08-29 | Boston Probes, Inc. | Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays |
| US20020034737A1 (en) | 1997-03-04 | 2002-03-21 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
| DE19712541C1 (de) | 1997-03-25 | 1998-11-05 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| US5843995A (en) | 1997-07-07 | 1998-12-01 | University Of Medicine And Dentistry Of New Jersey | Inhibition of HIV-1 replication using oligocarbamate derivatives |
| DE19735118C1 (de) | 1997-08-13 | 1998-08-13 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| DK1012348T3 (da) | 1997-09-16 | 2002-10-14 | Innogenetics Nv | Detektion og identifikation af humant papillomavirus ved PCR og typespecifik revers hybridisering |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| AU1232099A (en) | 1997-11-04 | 1999-05-24 | Roche Diagnostics Gmbh | Specific and sensitive method for detecting nucleic acids |
| JP2002508190A (ja) | 1997-12-12 | 2002-03-19 | ダイジーン・コーポレーション | 万能収集媒質 |
| US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
| ATE397086T1 (de) | 1997-12-22 | 2008-06-15 | Hitachi Chemical Co Ltd | Reinigung von mrna auf mikroplatten |
| WO1999036571A2 (en) | 1998-01-13 | 1999-07-22 | Biochip Technologies Gmbh | Method for the detection or nucleic acid of nucleic acid sequences |
| US7399589B2 (en) | 1998-02-06 | 2008-07-15 | Digene Corporation | Immunological detection of RNA:DNA hybrids on microarrays |
| US5994079A (en) | 1998-02-06 | 1999-11-30 | Digene Corporation | Direct detection of RNA mediated by reverse transcriptase lacking RNAse H function |
| US6686151B1 (en) | 1998-02-06 | 2004-02-03 | Digene Corporation | Immunological detection of RNA:DNA hybrids on microarrays |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| ES2212251T3 (es) | 1998-03-23 | 2004-07-16 | Spal S.R.L. | Ventilador de flujo axial. |
| US6183956B1 (en) | 1998-03-31 | 2001-02-06 | Tularik, Incorporated | High throughput in vitro screening assays for transcription modulators |
| US6045993A (en) | 1998-05-30 | 2000-04-04 | Visible Genetics Inc. | Method, reagent and kit for genotyping of human papillomavirus |
| US6284532B1 (en) | 1998-08-17 | 2001-09-04 | Indiana University | Purified human papillomavirus |
| DE19840263C1 (de) | 1998-09-03 | 2000-05-25 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
| ES2291039T3 (es) | 1998-09-04 | 2008-02-16 | Sanofi Pasteur Limited | Tratamiento del cancer cervical. |
| US7569344B2 (en) | 1998-10-26 | 2009-08-04 | Ventana Medical Systems, Inc. | Detection of human papilloma virus in papanicolaou (Pap) smears |
| US6951722B2 (en) | 1999-03-19 | 2005-10-04 | Takara Bio Inc. | Method for amplifying nucleic acid sequence |
| WO2000060116A1 (en) | 1999-04-02 | 2000-10-12 | Tropix, Inc. | High throughput and high sensitivity detection assays |
| US20010055766A1 (en) | 1999-04-02 | 2001-12-27 | Alexander Aristarkhov | Immunosorbant assay using branched bis-biotin/avidin/multiple label complex as a detection reagent |
| NZ514662A (en) | 1999-04-07 | 2004-01-30 | Sankyo Co | Amine derivatives |
| US6544732B1 (en) | 1999-05-20 | 2003-04-08 | Illumina, Inc. | Encoding and decoding of array sensors utilizing nanocrystals |
| US6420106B1 (en) | 1999-06-09 | 2002-07-16 | Quantovir Ab | Method and kit for early cancer prediction |
| US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| US20060275784A1 (en) | 1999-10-26 | 2006-12-07 | Ventana Medical Systems, Inc. | Detection of Human Papilloma Virus in Papanicolaou (Pap) Smears |
| US6893819B1 (en) | 2000-11-21 | 2005-05-17 | Stratagene California | Methods for detection of a nucleic acid by sequential amplification |
| DE10009143B4 (de) | 2000-02-26 | 2012-04-26 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Nachweis von Humanen Papillomviren |
| KR100382703B1 (ko) | 2000-03-15 | 2003-05-09 | 주식회사 바이오메드랩 | 인유두종바이러스의 유전형 진단키트 및 상기 진단키트의제조방법 |
| US6936443B2 (en) | 2000-04-03 | 2005-08-30 | Cytyc Corporation | Detection and typing of human papillomavirus using PNA probes |
| US7510834B2 (en) | 2000-04-13 | 2009-03-31 | Hidetoshi Inoko | Gene mapping method using microsatellite genetic polymorphism markers |
| US6828098B2 (en) | 2000-05-20 | 2004-12-07 | The Regents Of The University Of Michigan | Method of producing a DNA library using positional amplification based on the use of adaptors and nick translation |
| US6331423B1 (en) | 2000-06-01 | 2001-12-18 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| ES2287134T3 (es) | 2000-06-02 | 2007-12-16 | Bayer Corporation | Procedimiento para la deteccion y localizacion de genes in situ usando hibridacion de adn ramificado. |
| US7601497B2 (en) | 2000-06-15 | 2009-10-13 | Qiagen Gaithersburg, Inc. | Detection of nucleic acids by target-specific hybrid capture method |
| US7439016B1 (en) | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| JP2004508019A (ja) | 2000-07-28 | 2004-03-18 | コンピュジェン インコーポレイテッド | トランスクリプトームの中に場所を占めるｒｎａ転写物及びスプライス変異体を検出するためのオリゴヌクレオチドライブラリー |
| US6329152B1 (en) | 2000-11-30 | 2001-12-11 | Bruce K. Patterson | Process for detecting low abundance RNA in intact cells |
| JP2004518421A (ja) | 2000-12-12 | 2004-06-24 | インビトロジェン コーポレイション | 固体マトリックスから核酸分子を解放させるための組成物および方法 |
| WO2002066993A1 (en) | 2001-02-16 | 2002-08-29 | Cortex Biochem, Inc. | Magnetic isolation and purification of nucleic acids |
| US6670150B1 (en) | 2001-05-10 | 2003-12-30 | Applera Corporation | Isolated human receptor proteins, nucleic acid molecules encoding human receptor proteins, and uses thereof |
| US6884605B2 (en) | 2001-08-09 | 2005-04-26 | Board Of Trustees Of The University Of Arkansas | Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| EP1806410A3 (en) | 2001-08-23 | 2007-10-24 | Merck & Co., Inc. | Fluorescent multiplex HPV PCR assays using multiple fluorophores |
| KR100452163B1 (ko) | 2001-09-14 | 2004-10-12 | 주식회사 바이오메드랩 | 인유두종 바이러스의 감염을 진단하기 위한 유전형 분석키트 |
| US20050032105A1 (en) | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
| US6977148B2 (en) | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| PT1463839E (pt) | 2002-01-07 | 2007-05-31 | Norchip As | Método para detectar arnm de um vírus do papiloma humano |
| WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
| HUP0200981A3 (en) | 2002-03-14 | 2004-06-28 | Genoid Kft | Pcr reactions with hybridizing probes using primers with broad genotype-specificity for detection of human papilloma-viruses and typing amplificates by using specifically hybridizing oligonucleotides |
| US7531305B2 (en) | 2002-04-16 | 2009-05-12 | Autogenomics, Inc. | Human Papilloma Virus detection with DNA microarray |
| PT1506222E (pt) | 2002-05-17 | 2009-06-12 | Univ Cape Town | Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas |
| WO2004002416A2 (en) | 2002-06-26 | 2004-01-08 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
| SE0202896D0 (sv) | 2002-10-01 | 2002-10-01 | Quantovir Ab | Method for estimating the risk of carcinoma development |
| CN1720060B (zh) | 2002-10-03 | 2011-12-14 | 惠氏控股公司 | 人乳头瘤病毒多肽和免疫原性组合物 |
| CA2512110A1 (en) | 2002-12-31 | 2004-07-22 | Mmi Genomics, Inc. | Compositions, methods, and systems for inferring bovine breed |
| CA2519112C (en) | 2003-03-24 | 2012-09-11 | Merck & Co., Inc. | Optimized expression of hpv 31 l1 in yeast |
| WO2004087950A2 (en) | 2003-04-04 | 2004-10-14 | Roche Diagnostics Gmbh | Improved system for multi color real time pcr |
| US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| US20040248107A1 (en) | 2003-06-09 | 2004-12-09 | Sokolova Irina A. | Detection of high grade dysplasia in cervical cells |
| WO2005010145A2 (en) | 2003-07-05 | 2005-02-03 | The Johns Hopkins University | Method and compositions for detection and enumeration of genetic variations |
| ATE289685T1 (de) | 2003-08-25 | 2005-03-15 | Mtm Lab Ag | Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben |
| AU2004275865B2 (en) | 2003-09-25 | 2008-09-25 | Third Wave Technologies, Inc. | Detection of HPV |
| MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| WO2005033333A2 (en) * | 2003-10-07 | 2005-04-14 | Dako Denmark A/S | Methods and compositions for the diagnosis of cancer |
| US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| JP2005243132A (ja) | 2004-02-26 | 2005-09-08 | Renesas Technology Corp | 半導体装置 |
| ES2343255T3 (es) | 2004-03-24 | 2010-07-27 | MERCK SHARP & DOHME CORP. | Expresion optimizada del vph 52 l1 en levadura. |
| CN1690223B (zh) | 2004-04-27 | 2010-05-05 | 亚能生物技术（深圳）有限公司 | 人乳头瘤病毒分型基因芯片检测系统 |
| US7482142B1 (en) | 2004-05-07 | 2009-01-27 | Roche Molecular Systems, Inc. | High-risk human papillomavirus detection |
| EP3342877B1 (en) | 2004-09-30 | 2020-01-29 | Epigenomics AG | Method for providing dna fragments derived from an archived sample |
| US7670774B2 (en) | 2004-10-04 | 2010-03-02 | Goodgene Inc. | Probe of human papillomavirus and DNA chip comprising the same |
| US7354719B2 (en) | 2004-12-08 | 2008-04-08 | Gen-Probe Incorporated | Detection of nucleic acids from multiple types of human papillomaviruses |
| MX2007008553A (es) | 2005-01-14 | 2007-09-25 | Univ Michigan | Sistemas, metodos y composiciones para deteccion del virus de papiloma humano en muestras biologicas. |
| US20060240449A1 (en) | 2005-01-19 | 2006-10-26 | Mcglennen Ronald C | Methods and compositions for preparation of biological samples |
| US7524631B2 (en) | 2005-02-02 | 2009-04-28 | Patterson Bruce K | HPV E6, E7 mRNA assay and methods of use thereof |
| EP1928560A2 (en) | 2005-04-06 | 2008-06-11 | Verenium Corporation | Enzymes and formulations for broad-specificity decontamination of chemical and biological warfare agents |
| EP1880025B1 (en) | 2005-05-12 | 2011-03-16 | Affymetrix, Inc. | Multiplex branched-chain dna assays |
| US20080003565A1 (en) | 2006-05-02 | 2008-01-03 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Viral nucleic acid microarray and method of use |
| CA2652118C (en) | 2006-05-11 | 2015-07-07 | Becton, Dickinson And Company | Method of protein extraction from cells |
| WO2008139938A1 (ja) | 2007-05-02 | 2008-11-20 | National University Corporation Tokyo Medical And Dental University | ヒトパピローマウイルス１６型遺伝子を標的とする二本鎖核酸分子及びそれを含む医薬 |
| PL2479289T3 (pl) | 2007-06-08 | 2016-10-31 | Sposób analizy metylacji | |
| CN101177701B (zh) | 2007-09-29 | 2010-08-18 | 潮州凯普生物化学有限公司 | 人乳头状瘤病毒基因分型检测试剂盒及其基因芯片制备方法 |
| JP2009106220A (ja) | 2007-10-31 | 2009-05-21 | Genodive Pharma Kk | 基板上での等温増幅反応による標的塩基配列の捕捉及び検出方法 |
| ES2584228T3 (es) | 2007-11-01 | 2016-09-26 | Self-Screen B.V. | Nuevo método de detección para los HPV cervicales |
| US20110027798A1 (en) | 2008-03-31 | 2011-02-03 | The Ohio State University Research Foundation | Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides |
| WO2010004251A1 (en) | 2008-06-16 | 2010-01-14 | Oncomethylome Sciences Sa | Dna methylomes |
| WO2010028382A2 (en) | 2008-09-05 | 2010-03-11 | Mayo Foundation For Medical Education And Research | Collecting and processing complex macromolecular mixtures |
| US9090948B2 (en) | 2008-09-30 | 2015-07-28 | Abbott Molecular Inc. | Primers and probes for detecting human papillomavirus and human beta globin sequences in test samples |
| TWI394839B (zh) | 2008-10-27 | 2013-05-01 | Qiagen Gaithersburg Inc | 快速結果雜交捕捉法及系統 |
| EP2184368A1 (en) | 2008-11-07 | 2010-05-12 | DKFZ Deutsches Krebsforschungszentrum | Diagnostic transcript and splice patterns of HPV16 in different cervical lesions |
| JP5738278B2 (ja) | 2009-05-01 | 2015-06-24 | キアジェン ゲイサーズバーグ インコーポレイテッド | 試料中のｒｎａスプライシング形態を検出するための非標的増幅法 |
-
2011
- 2011-05-24 EP EP11726003.4A patent/EP2576840B1/en not_active Not-in-force
- 2011-05-24 CA CA2799205A patent/CA2799205A1/en not_active Abandoned
- 2011-05-24 WO PCT/US2011/037684 patent/WO2011149897A1/en not_active Ceased
- 2011-05-24 JP JP2013512140A patent/JP6153866B2/ja not_active Expired - Fee Related
- 2011-05-24 US US13/114,344 patent/US9376727B2/en not_active Expired - Fee Related
- 2011-05-24 AU AU2011258501A patent/AU2011258501B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011258501B2 (en) | 2016-07-07 |
| JP6153866B2 (ja) | 2017-06-28 |
| AU2011258501A1 (en) | 2013-01-10 |
| EP2576840A1 (en) | 2013-04-10 |
| US9376727B2 (en) | 2016-06-28 |
| JP2013534810A (ja) | 2013-09-09 |
| EP2576840B1 (en) | 2018-10-17 |
| US20120004128A1 (en) | 2012-01-05 |
| WO2011149897A1 (en) | 2011-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8877436B2 (en) | Fast results hybrid capture assay on an automated platform | |
| JP6104296B2 (ja) | 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット | |
| US9689047B2 (en) | Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids | |
| AU2012220575A1 (en) | Materials and methods for detection of HPV nucleic acid | |
| EP2529031B1 (en) | Method of determining and confirming the presence of hpv in a sample | |
| AU2011258501B2 (en) | Fast results hybrid capture assay and associated strategically-truncated probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150827 |
|
| FZDE | Discontinued |
Effective date: 20190904 |